NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer

Model scores of the 29,894 trials active now.

Model score 39% for any early termination, 25% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2019-01-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: everolimusscancarcinomasitucancer
  Phrases that lowered it: patients whotumorsbleedinghistoryinfluenza
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 29.1% (raises risk) · Drug's FDA history
• Responsible party: sponsor investigator (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: single group (raises risk) · Design
• Number of arms: 1 (raises risk) · Design
• Sponsor's past trials: 0 (raises risk) · Sponsor's track record
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Keywords listed: 0 (raises risk) · Design
• Collaborators: 1 (raises risk) · Design
• Blinding: none (raises risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Disease area, dermatology: Yes (raises risk) · Disease area
• Maximum age: not given (raises risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative NCT02456857 · started 2016 · scored riskier than 73% of active trials completed
• A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma NCT01797523 · started 2013 · scored riskier than 83% of active trials completed
• Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer NCT02228681 · started 2015 · scored riskier than 47% of active trials completed
• Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer NCT02531932 · started 2015 · scored riskier than 99% of active trials completed
• Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients NCT02152943 · started 2014 · scored riskier than 56% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.